Growth hormone-releasing hormone transforms therapeutic potential in health and chronic disease

From enhancing wound healing to combating neurodegeneration and cancer, growth hormone-releasing hormone and its analogs reveal groundbreaking roles that could redefine future therapies.

Study: Growth hormone-releasing hormone and its analogs in health and disease. Image Credit: Kateryna Kon / Shutterstock.com Study: Growth hormone-releasing hormone and its analogs in health and disease. Image Credit: Kateryna Kon / Shutterstock.com

In a recent study published in the journal Nature Reviews Endocrinology, researchers reviewed over four decades of research on the biological activities of growth hormone-releasing hormone (GHRH) and its analogs. The review presents in vitro and in vivo evidence for the beneficial roles of GHRH and its analogs in cell growth and wound healing, inflammation, cardiovascular diseases (CVDs), cancers, immunity, and psychiatric health, including neurodegenerative conditions.

What is GHRH?

Otherwise referred to as ‘somatoliberin,’ GHRH is a family of hypothalamic peptide hormones that trigger and modulate the synthesis and release of somatotropin or growth hormone (GH). First hypothesized in the 1960s, GHRH was clinically observed in the 1980s in carcinoid and pancreatic islet cells and subsequently isolated from human acromegaly-inducing pancreatic tumors.

Since then, extensive research on GHRH has led to the discovery of their functions including stimulation of the anterior pituitary gland to regulate GH concentrations, splice variants, and potential clinical applications. GHRH antagonists are of particular interest due to their anti-inflammatory, antitumor, and immunomodulatory activities.

GHRH analogs

Decades of research on GHRH has led to the discovery of several functions independent of GH modulation. Endogenous GHRH has an extremely short half-life and is highly susceptible to the action of endogenous proteolytic enzymes, thus limiting GHRH research efforts.

To overcome these limitations, researchers have developed synthetic GHRH analogs with improved stability through chemical alterations that make them resistant to degradation. There are three types of GHRH analogs, of which include agonists, antagonists, and GHRH receptors (GHRHRs).

GHRH analogs are synthesized by modifying amino acid residues along the N-terminal GRHR sequence, thereby retaining the functional efficacy of endogenous GHRH. The resultant synthetic peptides have been extensively investigated and appear to be involved in cell growth, repair, and chronic disease progression.

GHRH in cell growth, cancer proliferation, and wound repair

In addition to governing the GH-producing effects of the pituitary gland, GHRH is crucial for normal pituitary gland development, particularly during early life. Moreover, GHRH and its variants have been identified in a host of extrahypothalamic tissues, including carcinogenic tumors, where they perform mitogenic functions, thereby potentially accelerating cancer development and progression.

The GHRH SV1 variant has been extensively characterized, with research demonstrating that SV1-expressing cells depict abnormally high proliferation rates. In fact, SV1 activity has been observed in various cancer cells, including endometrial carcinoma and esophageal squamous cell carcinoma, wherein SV1 acts as a hypoxia-drive promoter of tumor progression.

Synthetic GHRH analogs, particularly GHRH(1–29)NH2 and JI-38, enhance the migration of embryonic fibroblasts to wound sites, thereby accelerating tissue repair following injury. Similarly, MR-409 and MR-502 have been shown to promote healing while simultaneously arresting fibrosis, thus underscoring their application in post-accident or post-surgery recovery.

GHRH in chronic disease

GHRH and its agonists have been implicated in several cardiovascular, metabolic, and nervous system conditions. For example, GHRH agonists enhance the regenerative potential of mesenchymal cells (MSCs), thereby combatting heart diseases.

GHRH binds to GHRHRs, leading to an increase in levels of cAMP, which potentially contributes to enhanced survival of cardiomyocytes, myocardial contractility and energy metabolism.”

GHRH may indirectly benefit cardiovascular health, such as through its effects on dyslipidemia. Dyslipidemia is a chronic and severe condition characterized by abnormal blood lipid concentrations. Tesamorelin, a GHRH agonist, has been shown to reduce cholesterol and low-density lipoprotein (LDL) levels, particularly in type 2 diabetes mellitus (T2DM) models.

The anti-inflammatory and antioxidant properties of GHRH analogs have also been observed in animal models for depression and anxiety. Furthermore, neuro-investigative studies have revealed unexpected effects of GHRH and its agonist in memory retention, cognition, and neurodegenerative disease progression.

Although some GHRH agonists like GHRH(1-44)NH2 have been shown to suppress memory retention, others, such as MR-409, can to arrest neural apoptosis and cell death, thereby slowing neurological aging. Together, these findings highlight the neurological potential of GHRH, supporting future research into its clinical application.

Conclusions

The present review highlights the cardiovascular, cancer, and neurological effects of some GHRH agonists and antagonists. Nevertheless, additional research is needed to elucidate the various mechanisms involved in the activity of GHRH and its analogs.

Journal reference:
  • Granata, R., Leone, S., Zhang, X. et al. (2024). Growth hormone-releasing hormone and its analogues in health and disease. Nature Reviews Endocrinology. doi:10.1038/s41574-024-01052-1
Hugo Francisco de Souza

Written by

Hugo Francisco de Souza

Hugo Francisco de Souza is a scientific writer based in Bangalore, Karnataka, India. His academic passions lie in biogeography, evolutionary biology, and herpetology. He is currently pursuing his Ph.D. from the Centre for Ecological Sciences, Indian Institute of Science, where he studies the origins, dispersal, and speciation of wetland-associated snakes. Hugo has received, amongst others, the DST-INSPIRE fellowship for his doctoral research and the Gold Medal from Pondicherry University for academic excellence during his Masters. His research has been published in high-impact peer-reviewed journals, including PLOS Neglected Tropical Diseases and Systematic Biology. When not working or writing, Hugo can be found consuming copious amounts of anime and manga, composing and making music with his bass guitar, shredding trails on his MTB, playing video games (he prefers the term ‘gaming’), or tinkering with all things tech.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Francisco de Souza, Hugo. (2024, November 17). Growth hormone-releasing hormone transforms therapeutic potential in health and chronic disease. News-Medical. Retrieved on December 04, 2024 from https://www.news-medical.net/news/20241117/Growth-hormone-releasing-hormone-transforms-therapeutic-potential-in-health-and-chronic-disease.aspx.

  • MLA

    Francisco de Souza, Hugo. "Growth hormone-releasing hormone transforms therapeutic potential in health and chronic disease". News-Medical. 04 December 2024. <https://www.news-medical.net/news/20241117/Growth-hormone-releasing-hormone-transforms-therapeutic-potential-in-health-and-chronic-disease.aspx>.

  • Chicago

    Francisco de Souza, Hugo. "Growth hormone-releasing hormone transforms therapeutic potential in health and chronic disease". News-Medical. https://www.news-medical.net/news/20241117/Growth-hormone-releasing-hormone-transforms-therapeutic-potential-in-health-and-chronic-disease.aspx. (accessed December 04, 2024).

  • Harvard

    Francisco de Souza, Hugo. 2024. Growth hormone-releasing hormone transforms therapeutic potential in health and chronic disease. News-Medical, viewed 04 December 2024, https://www.news-medical.net/news/20241117/Growth-hormone-releasing-hormone-transforms-therapeutic-potential-in-health-and-chronic-disease.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.